Abbisko’s pimicotinib wins FDA approval for TGCT

FDA approved Abbisko (02256.HK) and Merck KGaA’s CSF-1R inhibitor pimicotinib (PIMJETMI / Beijiemai, NCT05804045) for adult TGCT after NMPA, Canada and Switzerland clearances.

Abbisko’s pimicotinib wins FDA approval for TGCT
Key clinical and regulatory metrics from the MANEUVER Phase 3 trial and FDA approval.

What moved. Abbisko Therapeutics said the FDA approved pimicotinib (PIMJETMI / Beijiemai) for symptomatic tenosynovial giant cell tumor (TGCT) in adults where surgery may worsen function or cause serious complications, matching the U.S. regulator’s 10 Nov 2026 approval notice and Abbisko’s same-week Hong Kong filings.

The number. In the Phase 3 MANEUVER study (NCT05804045), blinded independent review by RECIST v1.1 at week 25 showed an objective response rate of 56% on drug versus 3% on placebo. Abbisko says this is the drug’s fourth major-market approval after China (Dec 2025), Canada (Jun 2026), and Switzerland (Oct 2026).

Why it matters. Global rights sit with Merck KGaA. A U.S. first commercial sale triggers another milestone for Abbisko, plus double-digit royalties on global net sales. For BD readers, this is a China-origin small molecule moving through a classic out-license path: local originator, multinational commercial owner, sequential major-market stamps.

Related on China Pharma Desk: Analysis: Abbisko’s staged $605.5m China-to-Merck licensing path · Analysis: Beijiemai’s China hospital launch and open NRDL question